Leber's Hereditary Optic Neuropathy - Pipeline Review, H1 2017 - Product Image

Leber's Hereditary Optic Neuropathy - Pipeline Review, H1 2017

  • ID: 4239800
  • Report
  • 55 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Biovista Inc
  • GenSight Biologics SA
  • Ixchel Pharma LLC
  • Khondrion BV
  • Mitotech SA
  • Spark Therapeutics Inc
  • MORE
Leber’s Hereditary Optic Neuropathy - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Leber’s Hereditary Optic Neuropathy - Pipeline Review, H1 2017, provides an overview of the Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline landscape.

Leber’s hereditary optic neuropathy (LHON) is an inherited form of vision loss. This condition usually begins in a person's teens or twenties, rare cases may appear in early childhood or later in adulthood. Males are affected much more often than females. Symptoms include eye pain or discomfort, numbness, tingling and clouding of vision. Predisposing factors include age, tobacco smoke, alcohol, cancer treating drugs, stress related chemicals, some antibiotics and cyanogens.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Leber’s Hereditary Optic Neuropathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 3, 2, 3, 1 and 1 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- The pipeline guide reviews pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Leber’s Hereditary Optic Neuropathy (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Leber’s Hereditary Optic Neuropathy (Ophthalmology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Leber’s Hereditary Optic Neuropathy (Ophthalmology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Leber’s Hereditary Optic Neuropathy (Ophthalmology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Biovista Inc
  • GenSight Biologics SA
  • Ixchel Pharma LLC
  • Khondrion BV
  • Mitotech SA
  • Spark Therapeutics Inc
  • MORE
Introduction

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Overview

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Companies Involved in Therapeutics Development

Alkeus Pharmaceuticals Inc

Biovista Inc

GenSight Biologics SA

Ixchel Pharma LLC

Khondrion BV

Mitotech SA

Spark Therapeutics Inc

Stealth BioTherapeutics Inc

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Drug Profiles

BVA-202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BVA-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drug for Lebers Hereditary Optic Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elamipretide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Activate ND4 for Leber's Hereditary Optic Neuropathy - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GS-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IXC-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IXC-203 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KH-176 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

plastoquinone decyl triphenylphosphonium bromide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SPK-LHON - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Product Development Milestones

Featured News & Press Releases

Feb 21, 2017: GenSight Biologics Completes Enrollment of REVERSE Phase III Study of GS010 in the treatment of Leber’s Hereditary Optic Neuropathy

Dec 20, 2016: GenSight Biologics Reports Sustained Visual Acuity Gain at 78 Weeks in Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON)

Sep 08, 2016: GenSight Biologics Receives Approval to Include Teenage Patients in RESCUE and REVERSE Phase III Trials with GS010 in Leber’s Hereditary Optic Neuropathy

Jun 08, 2016: GenSight Biologics Announces Additional Promising Results of Its Phase I/II Study with GS010 for the Treatment of Leber’s Hereditary Optic Neuropathy (LHON)

Jun 01, 2016: Stealth BioTherapeutics Initiates Phase 2 Study of Elamipretide in Leber's Hereditary Optic Neuropathy

Feb 29, 2016: GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy

Sep 10, 2015: GenSight Biologics Receives IND Acceptance from FDA to Enter Phase III with GS010

Dec 15, 2014: New CMO joins Khondrion

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Alkeus Pharmaceuticals Inc, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Biovista Inc, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by GenSight Biologics SA, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Ixchel Pharma LLC, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Khondrion BV, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Mitotech SA, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Spark Therapeutics Inc, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Pipeline by Stealth BioTherapeutics Inc, H1

Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy) - Dormant Projects, H1

List of Figures:

Number of Products under Development for Leber’s Hereditary Optic Neuropathy (LHON) (Leber optic atrophy), H1

Number of Products under Development by Companies, H1

Number of Products by Targets, H1

Number of Products by Stage and Targets, H1

Number of Products by Mechanism of Actions, H1

Number of Products by Stage and Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Alkeus Pharmaceuticals Inc
  • Biovista Inc
  • GenSight Biologics SA
  • Ixchel Pharma LLC
  • Khondrion BV
  • Mitotech SA
  • Spark Therapeutics Inc
  • Stealth BioTherapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll